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Purpose: Aqueous levels of vascular endothelial growth factor (VEGF) can be a surrogate 
marker of intraocular VEGF activity and a measure of efficacy of anti-VEGF treatment in 
a variety of vasoproliferative retinal disorders, including diabetic retinopathy, age-related 
macular degeneration, and central retinal vein occlusion. Measurement of the VEGF level 
may be adversely affected by premeasurement variables, such as freezing and delay, in sample 
analysis. We aim to evaluate the effect of storage and delayed measurement of human aqueous 
VEGF levels in these conditions.
Methods: Aqueous samples collected from patients receiving intravitreal injection of 
  bevacizumab for various retinal diseases were divided into two groups. In Group 1, the VEGF 
levels were analyzed on the same day; in Group 2, the VEGF levels were analyzed after 21 days 
of freezer storage (−80°C) using immunobead assay. Statistical comparison using a paired t-test 
was performed between the two groups.
Results: Thirty-one aqueous humor samples were collected, and the VEGF concentration for 
fresh samples was 7.8 ± 5.9 pg/mL (mean ± SD) compared to 6.5 ± 6.0 pg/mL in frozen samples, 
resulting in a statistically significant difference (P = 0.03).
Conclusions: Accurate measurement of the VEGF level is a vital component of clinical 
decision-making. Delayed analysis of VEGF levels in aqueous samples may result in significant 
sample degradation and lower levels of measured VEGF.
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Introduction
Vascular endothelial growth factor (VEGF), an endothelial cell mitogen, is implicated 
as a key factor in angiogenesis and increases vascular permeability.1,2 Increased 
l  evels of VEGF are observed in aqueous and vitreous humor in several ischemic 
ocular conditions, including diabetic retinopathy, retinal vascular occlusions, and 
age-related macular degeneration. As such, VEGF levels correlate with the severity 
of the disease process.3–10 Accurate assessment of VEGF in aqueous samples can be 
a useful tool in assessing the severity of disease, as well as in titrating the dosage of 
anti-VEGF therapy.
The most widely used enzyme-linked immunosorbent assay (ELISA) that measures 
VEGF levels in the aqueous samples analyzes one cytokine and requires a sample 
volume of at least 100 µL for detection of proteins such as VEGF.11 Recent c  ytometric 
bead immunoassay measurement of VEGF levels in aqueous samples has shown 
  superior accuracy in smaller volumes.6,12 Use of bead-based immunoassay is more 
accurate and cost effective than use of ELISA in measuring VEGF levels.13Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Aqueous samples are typically frozen at −80°C (a c  ommon 
clinical practice) if immediate measurement of cytokine is 
not feasible. Extrinsic factors, such as temperature, can alter 
the measurement of cytokine levels in biological fluids after 
storage.14,15 In this study, we compared the VEGF levels 
  estimated in a fresh sample with VEGF levels stored for 
21 days at −80°C and evaluated the effect of freezing on 
sample degradation using bead-based immunoassay.
Methods
sample collection
The study samples were obtained from 31 patients (mean 
age ± SD, 73.87 ± 9.29 years; male/female, 15/16) who were 
receiving intravitreal injection of bevacizumab for various 
retinal diseases. Of these, 18 patients had macular degenera-
tion, ten had cystoid macular edema, and three had diabetic 
macular edema. One hundred microliters of aqueous humor 
samples were obtained from the eye before administration 
of intravitreal injection. All samples were obtained with 
informed consent from the patient and approved by the 
i  nstitutional review board at the University of Florida.
Each sample was aliquoted into two subgroups. VEGF 
analysis was performed on the same day on samples that 
obtained from participants in Group 1. Samples from Group 2 
were stored in a −80°C freezer and analyzed after 3 weeks 
(21 days). All samples were stored in 1.5-mL self-standing 
screw cap polypropylene tubes (DNAse, RNAse, and   pyrogen 
free). The samples that were processed on the same day were 
referred as ‘fresh’, and the samples stored at −80°C were 
referred as ‘frozen’.
Usage of immunobead assay  
for VegF analysis
Both fresh and frozen samples were handled by the same 
experienced researcher. Samples were processed for VEGF 
  analysis at room temperature (RT) using immunobead assay 
by Luminex 100™ IS fluoroanalyzer (Tepnel Life   Sciences, 
San Diego, CA). Standards were reconstituted and   serially 
diluted as per manufacturer’s instructions (  Invitrogen 
  Corporation, Carlsbad, CA). To each well of 96-well microtiter 
plates, 25 µL of polystyrene microbeads and wash solutions 
were added and incubated for 30 sec. After the incubation 
time, the supernatant was washed off using vacuum manifold, 
  followed by the addition of incubation buffer and 50 µL each 
of sample and assay diluent. Diluted standards were added to 
the designated wells and the plate was incubated for 2 h at RT 
on an orbital shaker at 250–500 rpm. After incubation, the 
liquid was removed and the excess beads were washed off. 
Furthermore, 100 µL of detector antibody was added to each 
well and incubated on an orbital shaker at RT for 1 h. Excess 
detector antibodies were removed, followed by the addition of 
substrate c  omplex (Streptavidin R-Phycoerythrin [S-RPE]), 
and the fluorescence was measured using Luminex 100 IS 
  fluoroanalyzer after 30 min of incubation at RT. Both   negative 
and positive controls were included on each microtiter plate 
for each reaction. To ensure proper assay performance, a 
known concentration of human recombinant VEGF was 
included in each run (  positive control).
Analysis of VegF concentration
We measured the mean fluorescence of associated S-RPE 
with 100 beads that were bound to the VEGF in the sample. 
The resulting data was interpreted by curve-fitting algorithm 
using InStat data analysis software (GraphPad, San Diego, 
CA). VEGF levels were estimated based on the intensity of 
emitted fluorescence in each sample. Sample concentrations 
were expressed as pg/mL based on standard curves plotted 
using protein standards supplied with the kits (minimal 
detectable limit is 5.7 pg/mL; Invitrogen Corporation). The 
effect of dilution was corrected in determining final values.
statistical analysis
Statistical analysis was done using GraphPad InStat and 
Minitab 13 (Minitab, State College, PA) statistical packages. 
A paired t-test was used to compare the VEGF   concentration 
between the fresh and the frozen samples. The level of 
  statistical significance was set at P , 0.05.
Results
In our study, we analyzed 31 fresh and frozen a  queous humor 
samples to observe the difference in VEGF   concentration. Using 
this immunobead assay, we were able to detect the VEGF l  evels 
in all the samples (Table 1). The mean VEGF   concentration 
in the fresh samples was 7.8 ± 5.9 pg/mL (mean ± SD; range: 
1.12–25.4 pg/mL) compared with 6.5 ± 6.0 pg/mL (range: 
0.60–23.74 pg/mL) for the frozen samples (average of 17% 
reduction after freezing for 21 days).
Of the 31 samples analyzed, 24 samples showed more 
than 10% variation in VEGF levels after storage at −80°C 
compared with the fresh samples. Nineteen samples showed 
decreased VEGF levels and 12 samples showed increased 
VEGF levels after storage at −80°C. The observed difference 
was statistically significant in frozen samples in comparison 
with VEGF concentration in the fresh samples (P = 0.03; Fig-
ure 1). Table 2 shows the fresh and frozen aqueous individual 
and mean VEGF levels based on the clinical diagnoses.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Discussion
Anti-VEGF therapy, in the form of intravitreal injection, 
is the mainstay of therapy in the management of ischemic 
ocular conditions. VEGF levels in ocular fluids provide 
indirect evidence of severity of disease process and help 
in monitoring the therapeutic effects of anti-VEGF agents. 
Vitreous levels of secreted proteins or drugs have been used 
as a surrogate for retinal and choroidal levels, but vitreous 
taps or biopsies are not risk free and are usually obtained from 
patients undergoing surgery for different reasons. The use of 
an anterior chamber tap, at the time of intravitreal injection, 
to decompress the vitreous cavity has been found to be well 
tolerated. Studies are evaluating the potential usefulness of 
incorporating anterior chamber taps into clinical trials for 
measurement of molecular targets and drug levels (personal 
communication, DRCR.net).
Traditionally, ELISA is used to measure VEGF levels 
in the aqueous samples. Bead-based assay is fast r  eplacing 
ELISA for use in laboratories to quantify cytokines in 
  biological samples, such as serum, as bead-based assay is 
quicker to perform and is more efficient and cost effective.11,12 
The increased surface area provided by the microbeads 
Table 1 VegF levels in aqueous measured fresh and after storage at −80°C for 21 days
Sample no. (n = 31) Diagnosis Fresh VEGF levels 
on day 1 (pg/mL)
Frozen VEGF levels 
on day 21 (pg/mL)
Difference Percentage change 
from day 1
1 MD 5.60 0.60 −5.01 −89.36
2 CMe 6.80 5.22 −1.59 −23.34
3 MD 9.21 1.59 −7.62 −82.73
4 CMe 8.41 5.47 −2.94 −34.99
5 CMe 12.01 7.75 −4.26 −35.48
6 MD 2.11 2.00 −0.10 −4.94
7 MD 1.33 1.334 +0.00 +0.30
8 MD 6.26 1.73 −4.53 −72.39
9 MD 6.35 2.83 −3.52 −55.46
10 MD 7.47 2.28 −5.20 −69.54
11 CMe 1.12 0.63 −0.49 −43.93
12 DMe 25.40 8.17 −17.23 −67.84
13 CMe 17.81 19.41 +1.61 +9.03
14 MD 2.12 2.69 +0.57 +26.79
15 MD 2.04 1.93 −0.11 −5.29
16 MD 3.06 3.53 +0.46 +15.14
17 MD 2.04 2.90 +0.86 +42.06
18 DMe 3.95 3.00 −0.95 −23.96
19 MD 13.77 10.32 −3.45 −25.04
20 MD 4.20 2.93 −1.27 −30.17
21 CMe 4.94 3.08 −1.86 −37.68
22 CMe 17.45 23.74 +6.29 +36.07
23 CMe 13.04 11.24 −1.80 −13.80
24 DMe 13.42 16.04 +2.62 +19.54
25 MD 17.31 17.86 +0.55 +3.18
26 MD 4.06 4.63 +0.57 +13.94
27 CMe 5.99 8.00 +2.01 +33.60
28 MD 2.52 2.51 −0.01 −0.48
29 MD 8.27 11.50 +3.23 +39.01
30 CMe 4.54 3.63 −0.90 −19.93
31 MD 11.84 13.01 +1.17 +9.90
Abbreviations: MD, macular degeneration; CMe, cystoid macular edema; DMe, diabetic macular edema; VegF, vascular endothelial growth factor.
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Figure  1  Comparative  analysis  of  vascular  endothelial  growth  factor  (VegF) 
concentration between fresh and frozen samples.
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s  ignificantly reduces the required sample volume. In a  ddition, 
the sensitivity of the test is superior because fluorescence, 
rather than colorimetric measurement, is utilized. In our 
study, all the VEGF measurements were conducted using 
bead-based assay with standard VEGF concentrations 
as a positive control, which enhanced the validity of our 
results.
Recently, numerous studies evaluated the correlation 
between VEGF levels in the aqueous samples and severity 
of ocular ischemic process.3,16–18 The next step after find-
ing an appropriate correlation is to test whether the levels 
could be used to monitor the disease activity and response 
to treatment.15,16 Cytokines are usually not considered to 
be very stable after collection, which might artificially 
interfere with test results.15 Detected levels of cytok-
ines may be affected by methods of storage or repeated 
freezing–thawing.14
However, there have been no studies evaluating the effect 
of storage on measurement of VEGF levels in aqueous 
samples. Our study is the first of its kind to test the stability 
of VEGF in aqueous humor samples and provides evidence 
of variation in VEGF measurement after 3 weeks of storage. 
This is consistent with results reported by Rosenling et al19 
who observed a significant change in proteome-derived 
peptide profile in cerebrospinal fluid after storage for a week 
or 1 month, and with those of Aziz et al20 who reported a 
significant change in tumor necrosis factor alpha levels 
in plasma after storage, at 4°C or at −70°C for 20 days in 
comparison to samples stored at 24°C. This study’s results 
are also consistent with earlier study results on fresh versus 
frozen urine sample peptide concentration.21
We can only speculate as to the mechanism of variation 
in VEGF measurements in aqueous samples. One possible 
mechanism is the presence of different proteases in the 
aqueous sample, which could cause a true decrease in VEGF 
measurement.22 Another possible mechanism could be the 
result of alteration of the binding of detector antibody used 
during the assay, possibly from degradation, and a change in 
configuration of amino acids in VEGF protein due to delayed 
measurements.19 The presence of soluble VEGF receptors in 
aqueous samples and the possibility of alteration in protein 
folding after freezing can increase the competitive binding 
affinity of other VEGF isoforms and increase VEGF levels 
observed in some samples.
In conclusion, this pilot study showed a statistically sig-
nificant decrease in VEGF levels after storage for 3 weeks. 
Estimation of VEGF immediately after sample collection is 
recommended for accuracy.
Table 2 Vascular endothelial growth factor (VegF) levels in aqueous samples measured fresh and after storage at −80°C for 21 days 
based on clinical diagnosis
Serial no. Macular degeneration Cystoid macular edema Diabetic macular edema
Fresh VEGF  
levels on  
day 1 (pg/mL)
Frozen VEGF  
levels on  
day 21 (pg/mL)
Fresh VEGF  
levels on  
day 1 (pg/mL)
Frozen VEGF  
levels on  
day 21 (pg/mL)
Fresh VEGF  
levels on  
day 1 (pg/mL)
Frozen VEGF  
levels on  
day 21 (pg/mL)
1 5.60 0.60 6.8 5.22 25.40 8.17
2 9.21 1.59 8.41 5.47 3.95 3.00
3 2.11 2.00 12.01 7.75 13.42 16.04
4 1.33 1.334 1.12 0.63 – –
5 6.26 1.73 17.81 19.41 – –
6 6.35 2.83 4.94 3.08 – –
7 7.47 2.28 17.45 23.74 – –
8 2.12 2.69 13.04 11.24 – –
9 2.04 1.93 5.99 8.00 – –
10 3.06 3.53 4.54 3.63 – –
11 2.04 2.90 – – – –
12 13.77 10.32 – – – –
13 4.20 2.93 – – – –
14 17.31 17.86 – – – –
15 4.06 4.63 – – – –
16 2.52 2.51 – – – –
17 8.27 11.50 – – – –
18 11.84 13.01 – – – –
Col1 Col2  Col3 Col4 Col5 Col6 Col7
Mean 6.09 4.79 9.21 8.82 14.26 9.07
sD 4.55 4.90 5.64 7.41 10.75 6.57Clinical Ophthalmology
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